These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 29548035)

  • 1. Specific storage of glycoconjugates with terminal α-galactosyl moieties in the exocrine pancreas of Fabry disease patients with blood group B.
    Rybová J; Kuchar L; Hulková H; Asfaw B; Dobrovolný R; Sikora J; Havlícek V; Škultéty L; Ledvinová J
    Glycobiology; 2018 Jun; 28(6):382-391. PubMed ID: 29548035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defects in degradation of blood group A and B glycosphingolipids in Schindler and Fabry diseases.
    Asfaw B; Ledvinová J; Dobrovolńy R; Bakker HD; Desnick RJ; van Diggelen OP; de Jong JG; Kanzaki T; Chabas A; Maire I; Conzelmann E; Schindler D
    J Lipid Res; 2002 Jul; 43(7):1096-104. PubMed ID: 12091494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood group B glycosphingolipids in alpha-galactosidase deficiency (Fabry disease): influence of secretor status.
    Ledvinová J; Poupetová H; Hanácková A; Písacka M; Elleder M
    Biochim Biophys Acta; 1997 Apr; 1345(2):180-7. PubMed ID: 9106497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycosphingolipids and kidney disease.
    Mather AR; Siskind LJ
    Adv Exp Med Biol; 2011; 721():121-38. PubMed ID: 21910086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycosphingolipid profile of the apical pole of human placental capillaries: the relevancy of the observed data to Fabry disease.
    Hůlková H; Ledvinová J; Kuchař L; Šmíd F; Honzíková J; Elleder M
    Glycobiology; 2012 May; 22(5):725-32. PubMed ID: 22319058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosing lysosomal storage disorders: Fabry disease.
    Bodamer OA; Johnson B; Dajnoki A
    Curr Protoc Hum Genet; 2013; Chapter 17():Unit17.13. PubMed ID: 23595598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Norwalk virus-like particles bind specifically to A, H and difucosylated Lewis but not to B histo-blood group active glycosphingolipids.
    Nilsson J; Rydell GE; Le Pendu J; Larson G
    Glycoconj J; 2009 Dec; 26(9):1171-80. PubMed ID: 19387828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Neutral glycosphingolipids of Fabry's disease lymphoblastoid lines established by Epstein-Barr virus transformation].
    Salvayre R; Maret A; Negre A; Douste-Blazy L
    Eur J Biochem; 1985 Feb; 147(1):77-82. PubMed ID: 2982612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses.
    Ferraz MJ; Kallemeijn WW; Mirzaian M; Herrera Moro D; Marques A; Wisse P; Boot RG; Willems LI; Overkleeft HS; Aerts JM
    Biochim Biophys Acta; 2014 May; 1841(5):811-25. PubMed ID: 24239767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathophysiological aspects of brain structural disturbances in patients with Fabry disease: literature review].
    Nill M; Müller MJ; Beck M; Stoeter P; Fellgiebel A
    Fortschr Neurol Psychiatr; 2006 Dec; 74(12):687-95. PubMed ID: 17167727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycosphingolipid depletion in fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase.
    Abe A; Arend LJ; Lee L; Lingwood C; Brady RO; Shayman JA
    Kidney Int; 2000 Feb; 57(2):446-54. PubMed ID: 10652021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histochemical localization and analysis of blood group-related antigens in human pancreas using immunostaining with monoclonal antibodies and exoglycosidase digestion.
    Ito N; Nishi K; Nakajima M; Okamura Y; Hirota T
    J Histochem Cytochem; 1990 Sep; 38(9):1331-40. PubMed ID: 2387986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
    Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
    Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enzymatic diagnosis of Fabry disease using a fluorometric assay on dried blood spots: An alternative methodology.
    Caudron E; Prognon P; Germain DP
    Eur J Med Genet; 2015 Dec; 58(12):681-4. PubMed ID: 26520229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exocrine pancreatic insufficiency is not a cause of abdominal complaints in patients with Fabry disease.
    Vujasinovic M; Tepes B; Vujkovac B; Cokan Vujkovac A; Tretjak M; Korat V
    Wien Klin Wochenschr; 2015 Dec; 127(23-24):931-4. PubMed ID: 25835592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine dysfunction in patients with Fabry disease.
    Faggiano A; Pisani A; Milone F; Gaccione M; Filippella M; Santoro A; Vallone G; Tortora F; Sabbatini M; Spinelli L; Lombardi G; Cianciaruso B; Colao A
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4319-25. PubMed ID: 16926253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interdisciplinary approach towards female patients with Fabry disease.
    Weidemann F; Niemann M; Sommer C; Beer M; Breunig F; Wanner C
    Eur J Clin Invest; 2012 Apr; 42(4):455-62. PubMed ID: 22049975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histochemical reactivity of soybean agglutinin with blood group antigens and their precursor substances in acinar cells of human pancreas.
    Ito N; Nishi K; Nakajima M; Ishitani A; Okamura Y; Matsuda Y; Hirota T
    J Histochem Cytochem; 1987 Aug; 35(8):881-90. PubMed ID: 2955034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease.
    Eng CM; Guffon N; Wilcox WR; Germain DP; Lee P; Waldek S; Caplan L; Linthorst GE; Desnick RJ;
    N Engl J Med; 2001 Jul; 345(1):9-16. PubMed ID: 11439963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffuse structural and metabolic brain changes in Fabry disease.
    Marino S; Borsini W; Buchner S; Mortilla M; Stromillo ML; Battaglini M; Giorgio A; Bramanti P; Federico A; De Stefano N
    J Neurol; 2006 Apr; 253(4):434-40. PubMed ID: 16541218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.